Capula Management’s Aclaris Therapeutics ACRS Stock Holding History

Capula Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,593	Closed	-$23.9K	–	635
2025 Q1	$23.9K	Buy	+15,593	New	+$33.3K	﹤0.01%	669

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capula Management's ACRS Position: Q2 2025 in Review

Capula Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 15,593 shares — an estimated $23.9K sold.

Capula Management first reported a position in ACRS in Q1 2025 and held it in 1 quarter. The position peaked at $23.9K in Q1 2025. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

Capula Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
Capula Management sold 15,593 Aclaris Therapeutics shares in Q2 2025, an estimated $23.9K.
Capula Management first reported a position in Aclaris Therapeutics in Q1 2025 and held it in 1 quarter.
Capula Management's Aclaris Therapeutics position peaked at $23.9K in Q1 2025.
96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.